24–hour efficacy and safety of dorzolamide 2% versus brimonidine purite 0.15% each given twice daily when added to latanoprost 0.005% given each evening

Abstract

Abstract: : Purpose: To evaluate the efficacy and safety dorzolamide 2% versus brimonidine purite 0.15% each given twice daily added to latanoprost 0.005% given each evening. Methods: 33 patients were initiated on latanoprost therapy for up to six weeks and randomized to either dorzolamide or brimonidine purite for six weeks in a double–masked fashion (Period 1). Patients were then washed out of the treatment for six weeks and placed on the opposite therapy for six weeks (Period 2). Patients underwent diurnal curve intraocular pressure measurements at 08:00 and +4, +8, +12, +16, +20 and +24 hours at baseline and at the end of each treatment period. Results: See the table for intraocular pressure results. 

One patient was excluded from the evaluation due to a protocol violation and one patient discontinued early due to ocular intolerance on dorzolamide. Two patients had one time point excluded from the analysis, and thus the diurnal curve, due to failure to follow the protocol. Conclusions: This study suggests that dorzolamide and brimonidine purite both provide effective reduction in pressure when added to latanoprost over a 24–hour diurnal curve.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure